COMMUNIQUÉS West-GlobeNewswire

Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases
06/07/2026
CHICAGO, July 06, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an [...]
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
06/07/2026
Media Release COPENHAGEN, Denmark; July 6, 2026 TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2 ) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma [...]
Abivax Announces Closing of $920 Million Public Offering
06/07/2026
Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage [...]
Abivax annonce la réalisation de son offre au public de 920 millions de dollars
06/07/2026
Abivax annonce la réalisation de son offre au public de 920 millions de dollars PARIS, France, 6 juillet 2026 – 22h05 (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (« Abivax » ou la « Société [...]
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
06/07/2026
PDUFA Target Action Date Set for April 24, 2027 CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
06/07/2026
CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
06/07/2026
No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) [...]
Longeveron® Appoints Marie Washburn as Chief Financial Officer
06/07/2026
Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectors Corporate focus on delivering top-line results from the Phase 2b clinical trial evaluating its stem cell therapy [...]
Alberta Cancer Foundation invests $35-million to power cancer clinical trials for Albertans
06/07/2026
Historic funding over the next five years strengthens Alberta’s newly launched 10-Year Cancer Care Strategy CALGARY, Alberta, July 06, 2026 (GLOBE NEWSWIRE) -- The Alberta Cancer Foundation is investing $35-million to [...]
Clareo Plastic Surgery Named Best Plastic Surgery Practice in Boston
06/07/2026
Cliche Magazine Recognizes Clareo for Excellence in Cosmetic Procedures Chestnut Hill, MA, July 06, 2026 (GLOBE NEWSWIRE) -- Clareo Plastic Surgery has been honored as the best plastic surgery practice in Boston, [...]
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
06/07/2026
Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/07/2026
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
06/07/2026
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, [...]
Vireo Growth Inc. Engages Independent Trading Group (ITG), Inc. as Market Maker
06/07/2026
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that it has engaged the services of Independent Trading Group ("ITG") to provide [...]
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
06/07/2026
Company announcement No. 31 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 27, 2026) Copenhagen, Denmark, July 6, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 27 - 2026
06/07/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 30 juin au 3 juillet 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
06/07/2026
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non- [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026
06/07/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 30th June to 03rd July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument [...]
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
06/07/2026
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]

Pages